EI
IMNM icon

EAM Investors’s Immunome IMNM Stock Holding History

EAM Investors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,757
Closed -$1.57M – 334
2026
Q1 		$1.57M Buy
+71,757
New +$1.6M 0.18% 181
2024
Q2 		– Sell
-127,980
Closed -$3.16M – 294
2024
Q1 		$3.16M Buy
+127,980
New +$2.6M 0.49% 114

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

EAM Investors's IMNM Position: Q2 2026 in Review

EAM Investors sold out of Immunome (IMNM) in Q2 2026, closing a stake of 71,757 shares — an estimated $1.57M sold.

EAM Investors first reported a position in IMNM in Q1 2024 and held it in 2 quarters. The position peaked at $3.16M in Q1 2024. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • EAM Investors reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 71,757 Immunome shares in Q2 2026, an estimated $1.57M.
  • EAM Investors first reported a position in Immunome in Q1 2024 and held it in 2 quarters.
  • EAM Investors's Immunome position peaked at $3.16M in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.